Efficacy of intravesical pentosan polysulfate sodium in cats with obstructive feline idiopathic cystitis by Delille, Mareike et al.
Journal of Feline Medicine and Surgery
2016, Vol. 18(6) 492 –500
© ISFM and AAFP 2015





Feline idiopathic cystitis (FIC) is a common condition in 
cats presented at small animal clinics, and is character-
ised as sterile inflammation of the bladder in absence of 
a known cause.1 The aetiology of FIC is most likely mul-
tifactorial.2 Supporting a defect in the natural glycosami-
noglycan (GAG) layer of the urothelium as a contributing 
factor are the significantly decreased urine GAG/creati-
nine ratios in cats with FIC compared with normal cats.3 
The surface of the bladder mucosa is lined by GAGs4 and 
proteoglycans.5,6 GAGs are mucopolysaccharide chains 
built of unbranched polysaccharide molecules.7 Their 
major function is to prevent the adhesion of noxious sub-
stances (microbes, microcrystals, protein, ions, carcino-
gens and toxic waste products of metabolism) to the 
bladder wall.4,8,9 Therefore, a defect GAG layer leads to 
increased exposure of the urothelium to noxious sub-
stances. In addition, epithelial defects and decreased 
transepithelial resistance have been identified in cats 
with FIC.10 These alterations can allow potentially harm-
ful substances of the urine access to the lamina propria, 
resulting in chronic immune-mediated or neurogenic 
inflammation, mast cell activation and C-fibre stimula-
tion in the submucosa.11 A defective GAG layer in the 
urinary bladder has been associated with interstitial cys-
titis (IC) in humans as well.12–14
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Abstract
Objectives Obstructive feline idiopathic cystitis is a common emergency in small animal practice. There is 
evidence for a defective glycosaminoglycan layer in the urinary bladder of affected cats. The aim of this study was 
to investigate the effect of intravesical pentosan polysulfate sodium (PPS) in cats with obstructive feline idiopathic 
cystitis in a randomised, placebo-controlled, blinded clinical study.
Methods Thirty-five cats with obstructive feline idiopathic cystitis were enrolled into the study. On day 0, cats 
were randomised to receive either 30 mg PPS in saline (18 cats) or saline alone as placebo (17 cats) at the time 
of indwelling urinary catheter placement and then after 24 and 48 h. The catheter was clamped for 30 mins after 
administration before connecting it to a sterile urine collection system. The procedure was repeated after 24 and 
48 h, and then the indwelling catheter was removed. Treatment success was assessed via the incidence of recurrent 
urethral obstruction, results of a scoring system for physical examination and daily urinalysis from day 0 to 5.
Results Recurrent urethral obstruction occurred in 3/18 cats of the verum group and 3/17 of the placebo group 
(P = 1.000). The verum group showed a significantly lower degree of microscopic haematuria between day 5 and 
day 0 (P ⩽0.05). The placebo group showed a significantly lower degree of dipstick haematuria between day 5 and 
day 0 (P ⩽0.05). There was no difference in the clinical score between the groups in the investigated time period.
Conclusions and relevance Intravesical instillation of PPS three times within 48 h in the chosen dose had no influence 
on the incidence of recurrent urethral obstruction and clinical signs in cats with obstructive feline idiopathic cystitis.
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The most common clinical signs of FIC are a combina-
tion of haematuria, pollakiuria and periuria, as well as 
stranguria and dysuria.4,12 Urethral obstruction (UO) in 
FIC can occur due to inflammation and spasms, or for-
mation of a matrix-crystalline plug, which is mostly seen 
in male cats because of their long and narrow ure-
thra.11,15,16 UO is a life-threatening emergency17 and 
expensive to manage. Recurrent urethral obstruction 
(rUO) is a major problem in affected cats. The proportion 
of cats with rUO varies from 22% to 58% of affected 
cats18–20 within an observation period of up to 6 months. 
The high recurrence rate often leads to frustration and 
even euthanasia. Long-term follow-up of male cats with 
obstructive lower urinary tract disease (LUTD) revealed 
that 21% of the patients were euthanased because od 
rUO.18 It is therefore essential to find treatments that 
reduce the high rate of rUO, ease the pain and accelerate 
the healing process.
Pentosan polysulfate sodium (PPS) is a semi-synthetic 
sulfated proteoglycan similar in function and structure 
to heparin and GAG.21 PPS is supposed to replace dam-
aged or missing parts in the endogenous GAG layer of 
the bladder wall.21,22 In humans, PPS has been proven to 
be safe, and intravesical instillation induced significant 
improvement of clinical signs in a placebo-controlled 
clinical study in women with IC.22,23 In cats, neither 
adverse nor beneficial effects were seen after oral24 and 
subcutaneous25 administration of PPS. In a recently per-
formed pilot study in which cats were treated intravesi-
cally with a high dose of a solution containing hyaluronic 
acid (HA), chondroitin sulfate (CS) and N-acetyl-D glu-
cosamine, statistically significant differences were not 
observed between the groups regarding rUO and pain 
score.26
The hypothesis of the present study was that repeated 
intravesical instillation of PPS would help to reduce 
inflammation in the urinary bladder and accelerate 
regeneration and restitution of the urothelium. This 
should also lead to a more rapid healing process and 




The study had a prospective randomised, placebo- 
controlled, double-blind design. All cats were treated at 
the Clinic of Small Animal Medicine, LMU, Munich, from 
June 2011 to June 2014. The study was approved by the 
Government of Upper Bavaria (reference number 55.2-1-
54-2532-8-12). Written informed consent was obtained 
from all owners before including their cats in the study.
Patients
All of the cats presenting with obstructive LUTD during 
this time period were screened for study eligibility. FIC 
was diagnosed by exclusion of other diseases of the 
lower urinary tract. Initial diagnostic investigations 
included a complete urinalysis (urine specific gravity 
[Reichert Vet 360]), urine dipstick (Combur 9 Test, Roche 
Diagnostics GmbH), urine sediment, aerobic urine cul-
ture, as well as abdominal radiographs visualising the 
complete urethra and abdominal ultrasound. A com-
plete blood count, serum chemistry profile and venous 
blood gas were performed on admission day (day 0) 
and repeated on day 1 and 2 if changes were observed 
on day 0 or 1, respectively. Total thyroxine was meas-
ured in all cats older than 8 years of age, and all cats 
were tested for feline immunodeficiency virus (FIV) and 
feline leukaemia virus (FeLV), if the status was 
unknown. Cats were excluded if urolithiasis or severe 
crystalluria were identified, if structural abnormalities 
were observed on ultrasound, or if neurological deficits 
were noted on physical examination. Cats were also 
excluded if other diseases, such as chronic kidney dis-
ease, diabetes mellitus or hyperthyroidism, were identi-
fied, or if they had been treated with steroids, 
antimicrobial drugs or GAGs within the past 14 days. 
Any bacterial growth on urine samples obtained by cys-
tocentesis on admission led to retrospective exclusion of 
affected cats (Figure 1).
Randomisation and study medication
A total of 52 cats were initially screened for enrolment 
into the study. Eight cats were excluded before randomi-
sation. The remaining 44 cats were randomly assigned to 
either the verum group (22 cats) or the placebo group 
(22 cats; Figure 1). Randomisation was conducted by 
rolling a dice. Numbers 1, 3 and 5 were assigned to group 
A, and numbers 2, 4 and 6 to group B. Study medications 
were drawn up by the clinical pharmacist. Verum and 
placebo were not distinguishable and were instilled by 
the treating veterinarian. Neither the veterinarian nor 
the owner was aware to which group the cat had been 
assigned. After the study was completed, all of the 
patients were decoded and data entered for statistical 
evaluation.
All of the cats received intravenous fluids and 
buprenorphine, and as soon as they were clinically sta-
ble, an indwelling urinary catheter (silicon feeding tube, 
CH 4.5, 1.0 mm × 1.5 mm, Braun) was placed aseptically 
under anaesthesia. The urinary bladder was completely 
drained and flushed with warm sterile solution of 
sodium chloride until the urine appeared macroscopi-
cally clear. The study medication (30 mg PPS = 0.3 ml 
[Pentosanpolysulfat SP 54 100 mg] Injektionslösung, 
bene Arzneimittel GmbH) in 10 ml sterile solution of 
sodium chloride (verum) or placebo (10 ml sterile solu-
tion of sodium chloride, 0.9%) was instilled into the 
 urinary bladder via the urinary catheter. After adminis-
tration, the catheter was clamped for 30 mins before 
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connection to a sterile urine collection system. The 
assigned drug was repeatedly administered after 24 and 
48 h. The urine collection bag was placed well below the 
cat to avoid reflux of urine. The urinary catheter was 
removed after 48 h. A new catheter was placed for 
another 24 h if cats did not urinate within 8 h after remov-
ing the first urinary catheter despite showing voiding 
attempts.
In addition to intravenous fluids, a treatment protocol 
used by Cooper et al27 was adapted and applied during 
the hospitalisation period (Table 1).
During hospitalisation, all cats were offered a canned 
urinary diet in addition to what they were used to eating 
at home. A definitive diet change, measures to increase 
water intake and multimodal environmental modifica-
tion were planned as long-term therapy at home.
Urinalysis
Urine samples were collected by transcutaneous cystocente-
sis on day 0, and catheter-derived on days 1 and 2. Urine 
samples were submitted for aerobic culture on days 0 and 2. 
Voided urine samples – collected by Katkor (Non Absorb 
Cat Litter) – were used for analysis on days 3, 4 and 5 in 
cats without rUO (n = 29), and catheter derived samples 
were used if cats suffered from rUO (n = 6). Urinalysis (dip-
stick, USG, sediment) was always performed within 30 mins 
Assessed for eligibility (n = 52)
Excluded (n = 8)
♦ Severe crystalluria/urolithiasis (n = 4)
♦ Uroabdomen (n = 1)
♦ Declined to participate (n = 2)
♦ Premedication with antibiotics (n = 1)
Enrolment
Randomised (n = 44)
Allocation
Placebo group
‘Intravesical Placebo 3 times within 48 h’
♦ Allocated to placebo group (n = 22)
♦ Received placebo (n = 21)
♦ Did not receive allocated intervention
(coagulation abnormality) (n = 1)
Treatment group
‘Intravesical PPS 3 times within 48 h’
♦ Allocated to treatment group (n = 22)
♦ Received treatment (n = 21)
♦ Did not receive allocated intervention





(death) (n = 1)
Discontinued intervention 
(owner decision to euthanize) (n = 1)
Analysed (n = 17)
♦ Excluded from analysis 
(positive urine culture) (n = 3)
Analysed (n = 18)
♦ Excluded from analysis 
(positive urine culture) (n = 2)
Analysis
Figure 1 Flow chart of progress through phases of trial
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after sampling. Urine was centrifuged at 2000 revolutions per 
min (rpm) for 5 mins. Twenty high-power fields (hpf; 400-
fold amplification) of the unstained urine sediment were 
investigated microscopically (Table 2).
Evaluation of treatment success
The main parameter for treatment success was the recur-
rence of UO and need for repeated catheterisation. The 
results of daily physical examinations and urinalyses 
were compared within the groups (day 0 with day 1, 2, 3, 
4 and 5) and between groups on each day (0–5). In addi-
tion, a clinical score including parameters of urinalysis 
and the physical examination was developed (Table 2 
and 3) and calculated daily. Each of the included param-
eters was graded according to severity from 0 to 4 for 
urinalysis results and from 0 to 3 for physical examina-
tion findings (Tables 2 and 3). Comparison of scores 
within treatment groups between individual days and 
comparison of scores between treatment groups on each 
day were performed. The highest score possible was 29 
points per day.
Statistical analysis
GraphPad Prism 5 (v5.04 for Windows, 2010) was used 
for statistical analysis. Data were investigated for normal 
distribution using the Kolmogorov–Smirnov test and 
D’Agostino and Pearson omnibus normality test. The 
Kruskal–Wallis test and Dunn’s multiple comparisons 
test were used for comparisons of continuous variables 
within groups and between groups at different time 
points. The Mann–Whitney U-test was used for compar-
ison of continuous variables between groups at entry 
into the study. For evaluation of categorical data, the χ2 
test was performed. Values of P ⩽0.05 were considered 
significant.
Results
There was no significant difference between cats of the 
PPS and the placebo group regarding signalment 
(Table  4), physical examination findings (Table 5) and 
laboratory parameters (Table 6) evaluated on admission.
UO recurred within the 4-day observation period 
after removal of the urinary catheter in three cats of the 
PPS group (16.7%) on days 3, 4 and 5, and in three pla-
cebo-treated cats (17.6%) on days 2, 3 and 4 (P = 1.000). 
Both groups showed a general amelioration in general 
demeanour, pain on abdominal palpation and appetite, 
with the greatest improvement from day 0 to day 1. 
Differences between the two groups were not observed 
at any time point (Table 7).
Within both treatment groups, results of urinalysis 
improved over time. However, differences between 
groups were not observed on any day. The degree of 
microscopic haematuria was significantly lower in the 
verum group on day 5 compared with day 0 (P ⩽0.05; 
Table 7). Proteinuria was significantly lower in the 
verum group on day 4 compared with day 0 (P ⩽0.05). 
Dipstick haematuria was significantly lower in the pla-
cebo group on day 5 compared with day 0 (P ⩽0.05). 
Proteinuria was significantly lower in the placebo group 
on day 2 (P ⩽0.05) and 3 (P ⩽0.01) compared with day 0 
(Table 7).
The clinical score decreased throughout the investiga-
tion period in both treatment groups without significant 
differences between groups at any time point.
Discussion
In this study, the effect of intravesically administered 
PPS in cats with obstructive FIC was investigated. PPS is 
a heparin-like semi-synthetic sulfated polysaccharide 
that resembles endogenous GAGs.28 The exact mecha-
nism of PPS is not yet known. One widely accepted 
hypothesis is that PPS repairs missing parts in the dam-
aged GAG layer.21 PPS is a common oral medication in 
the management of IC in humans,29 and oral treatment 
with PPS over a 32-week period induced clinical 
improvement that paralleled improvement of intravesi-
cal potassium sensitivity tests, indicating decreased per-
meability of the bladder epithelium after treatment with 
PPS.30 In addition, PPS has anticoagulatory and fibrino-
lytic properties.28,31 In vitro, PPS has been shown to 
inhibit nuclear factor-κB (activated by chronic inflamma-
tory diseases) and consequently to reduce inflammation 
of the bladder mucosa.32 Two additional in vitro studies 
reported an inhibition of mast cell stimulation by PPS 
that resulted in a reduction of histamine secretion.33,34 
Long-term oral supplementation of PPS (6–8 months) in 
women with IC appears to reduce pain (42–62%) and 
urgency (35–56%) successfully.29,35,36 Various studies 
demonstrated that PPS is more efficacious than placebo 
in the treatment of IC associated pain, urgency and fre-
quency.21,37,38 However, there are still patients with 
unsatisfactory responses to treatment. A possible reason 
for this might be that no more than 6% of the orally 
administered dose is excreted via urine.39 Therefore, 
intravesical administration in addition to oral PPS was 
investigated in IC patients. The addition of intravesically 
administered PPS resulted in a significant improvement 
Table 1 Supportive therapy used in the study in cats in 
both groups
Drug Dosage Day of 
treatment
Buprenorphine* 0.01 mg/kg IV q8h 0–5
Phenoxybenzamine† 0.5 mg/kg PO q24h 3–14
Acepromazine‡ 0.05 mg/kg IV q8h–q12h 1–2
*Vetergesic, Ecuphar GmbH
†Dibenzyran 5, Aristo Pharma GmbH
‡Vetranquil 1%, Albrecht GmbH
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in the severity of clinical signs compared with the con-
trol group that were only treated orally.22 Adverse effects 
were uncommon in humans but can consist of diarrhoea, 
nausea, alopecia and headache.28,35,36,40,41
In cats, PPS administered subcutaneously25 for 5 days 
or orally for 6 months42 did not result in significant differ-
ences in clinical signs and recurrence rates compared with 
the control groups. Oral administration of N-acetyl-D-
glucosamine for a period of 6 months did not show any 
effect in cats with FIC either.24 The present study investi-
gated the hypothesis that intravesical instillation of PPS in 
cats might provide a beneficial approach in treating cats 
with obstructive FIC. However, in this study, the response 
of the cats to intravesically administered PPS was not of 
any clinical benefit. Possible reasons for the lack of effi-
cacy could be the dose, the dosage and the residence time 
of PPS in the urinary bladder in this study. The dose used 
in the present study (30 mg per cat) was extrapolated from 
human medicine, as women receive an instillation of 
200–300 mg per session.22,23 This dose might not have been 
adequate for instillation in cats, and a higher concentra-
tion in the urinary bladder could produce greater effects. 
In addition, all of the cats enrolled in the present study 
were obstructed, whereas UO is only a rare feature in 
Table 2 Scoring system for urine parameters according to severity
Parameter Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Haematuria, dipstick Negative 1+ 2+ 3+ 4+
Proteinuria, dipstick Negative 1+ 2+ 3+ 4+
Erythrocytes/hpf 0–4 5–15 16–50 51–100 >100
Leukocytes/hpf Negative 0–5 6–12 13–19 >20
Macroscopic haematuria Negative Positive  
Urine cloudy/flakes Negative Positive  
hpf = high-power field
Table 3 Scoring system for clinical parameters according to severity
Parameter Grade 0 Grade 1 Grade 2 Grade 3
General demeanour Normal Mildly depressed Moderately depressed Severely depressed
Appetite Normal Mildly decreased Moderately decreased Severely decreased
Size of bladder Normal Mildly enlarged Moderately enlarged Severely enlarged
Abdominal pain  
on palpation
None Slightly painful Moderately painful Severely painful
Table 4 Signalment of cats in the pentosan polysulfate sodium (PPS) group and placebo group on admission
Parameter PPS (n = 18) Placebo (n = 17) P value
Sex, male Intact (n = 3) Intact (n = 3) 0.939*
 Neutered (n = 15) Neutered (n = 14)  
Breed DSH (n = 12) DSH (n = 14) 0.515*
 Purebred (n = 6) Purebred (n = 3)  
 (3 Persian, 3 Carthusian) (1 Persian, 2 Carthusian)  
Episodes 1st (n = 12) 1st (n = 12) 0.521*
 2nd (n = 6) 2nd (n = 6)  
Age in years, median  
(range)
6.4 (2–10.5) 5 (1–15) 0.582†
Body weight in kg,  
median (range)
5.85 (4.5–8.3) 5.8 (3.8–7.1) 0.438†
Body condition score,  
median (range)
6/9 (4/9–9/9) 6/9 (5/9–8/9) 0.107*
*χ2 test
†Mann–Whitney U-test
DSH = domestic shorthair
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women with IC.37,38 Post-obstructive diuresis is a common 
feature after relief of UO.43 Thus, diuresis could have led 
to a dilution of the medication in the urinary bladder and 
inadequate PPS concentrations in the urine. Potentially 
higher doses of PPS compensating for the dilution in post-
obstructive diuresis might be beneficial. Another approach 
could be to increase the frequency of PPS instillation 
(eg, q12h within 2 days) or a longer duration of catheteri-
sation with more frequent instillations of the medication. 
This may result in a more continuous supplementation of 
exogenous GAGs to the bladder wall. One disadvantage 
of such an approach is the higher incidence of catheter-
associated bacterial infection accompanying extended 
treatment with indwelling urinary catheters.44
In IC, women are advised to hold the instilled medica-
tion for 30 mins.22 Therefore, the indwelling urinary cathe-
ter was clamped for the same amount of time. Extending 
the residence time of PPS may permit the instilled drug 
additional time to take an effect. However, this prolonged 
iatrogenic obstruction might increase pressure in the uri-
nary bladder which may cause more discomfort for the cat.
The urothelial GAG layer is a combination of mainly 
heparan sulfate and CS and minor components, such as 
HA, dermatan sulfate and keratan sulfate. A combination 
of different GAGs (CS, HA and N-acetyl-glucosamine) in 
high concentrations was administered intravesically to 
cats with obstructive FIC in a recently published placebo-
controlled pilot study. In this study, the main parameter 
assessed to determine treatment success was the occur-
rence of rUO. None of the seven cats in the treatment 
group and three of nine cats (3/9, 33.3%) in the placebo 
group showed rUO. Although the results were not statis-
tically significant, the need is noted for further investiga-
tion with a larger study group.26
In the present study, the rates of rUO in the PPS and pla-
cebo group (16.7% and 17.6%, respectively) were lower 
than previously reported with recurrence rates of 58% 
within 3 days and 36% within 17 days,18,20 whereas other 
studies observed a recurrence rate of 15% (observation 
period of 2 months) in cats with UO of any cause and 22% 
(observation period of 6 months) in cats with obstructive 
FIC.19,45 Variable inclusion criteria (FIC and UO of any 
cause), study designs (prospective and retrospective), as 
well as a different medical management  (eg, use of 
α-sympatholytic drugs or no α-sympatholytic drugs) and 
follow-up periods could have influenced the different rates 
of rUO. The generally low recurrence rate of the present 
study population might have obscured the beneficial effects 
Table 6 Concentration of blood urea nitrogen (BUN), creatinine (CREA) and potassium of the pentosan polysulfate 
sodium (PPS) group and placebo group on admission
Parameter PPS (n = 18) Placebo (n = 17) Reference interval P value
BUN mmol/l, 
mean ± SD
34.83 ± 29.51 31.08 ± 36.53 5–11.3 0.228*
CREA µmol/l, 
mean ± SD
585.81 ± 652.39 550.23 ± 686.03 0–169 0.563*
Potassium mmol/l, 
mean ± SD*
5.24 ± 2.13 4.95 ± 2.21 3.5–5.6 0.775*
*Mann–Whitney U-test
Table 5 Initial physical examination of the cats in the pentosan polysulfate sodium (PPS) group and placebo group
Parameter PPS (n = 18) Placebo (n = 17) P value
General condition NAD 0 3 0.068*
 Minor 11 4
 Moderate 6 4
 Profound 1 6
Temperature °C, mean ± SD 38.07 ± 1.18 38.03 ± 0.99 0.999†
Heart rate Per minute, mean ± SD 186.17 ± 33.75 172.06 ± 30.13 0.289†
Respiratory rate Per minute, mean ± SD 37.62 ± 26.17 47.93 ± 31.60 0.311†
Abdominal pain on palpation NAD 0 0 0.089*
 Minor 2 2
 Moderate 6 6
 Profound 10 9
*χ2 test
†Mann–Whitney U-test
NAD = no abnormalities detected
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Table 7 Score for clinical and laboratory parameters in cats receiving pentosan polysulfate sodium (PPS) and placebo 
treatments, including the mean values, standard deviations and P values of the changes over time within each group 
(day 0 vs 1, day 0 vs 2, day 0 vs 3, day 0 vs 4, day 0 vs 5) and comparisons of groups on days 0, 1, 2, 3, 4 and 5
Variable Day Number of collected 
data
Mean ± SD 
PPS





P value* day 
0 vs 1, 2, 3, 
4, 5 PPS
P value* day 
0 vs 1, 2, 3, 
4, 5 placebo
































































































































































































17 16 3.88 ± 0.49 3.94 ± 0.25 ns  
17 16 3.38 ± 0.94 3.81 ± 0.54 ns ns ns
16 14 3.47 ± 1.10 3.64 ± 0.93 ns ns ns
16 13 3.33 ± 1.03 3.54 ± 0.88 ns ns ns
9 12 2.88 ± 1.32 2.83 ± 1.47 ns ns ns




0 18 17 2.71 ± 0.84 2.41 ± 0.71 ns  
1 15 16 2.64 ± 0.99 2.38 ± 0.72 ns ns ns
2 13 15 2.25 ± 1.07 1.47 ± 0.74 ns ns ⩽0.05
3 11 12 2.20 ± 0.87 1.33 ± 0.65 ns ns ⩽0.01
4 9 11 1.87 ± 0.83 1.91 ± 1.04 ns ⩽0.05 ns




0 17 17 2.53 ± 0.81 2.47 ± 0.79 ns  
1 17 17 2.25 ± 1.10 2.47 ± 0.63 ns ns ns
2 18 15 2.06 ± 1.09 2.07 ± 1.09 ns ns ns
3 17 15 1.71 ± 0.96 2.47 ± 0.83 ns ns ns
4 13 11 1.60 ± 1.12 1.91 ± 1.30 ns ns ns
5 13 10 1.50 ± 0.97 1.60 ± 1.07 ns ⩽0.05 ns
Leukocytes/hpf 
(grade 1–4)
0 16 16 1.13 ± 0.54 1.31 ± 0.87 ns  
1 16 17 1.40 ± 0.73 1.24 ± 0.83 ns ns ns
2 16 15 1.33 ± 0.60 1.47 ± 0.92 ns ns ns
3 15 15 1.29 ± 0.82 1.20 ± 0.94 ns ns ns
4 11 12 1.50 ± 1.04 1.33 ± 0.89 ns ns ns
5 13 10 1.33 ± 0.77 1.20 ± 1.03 ns ns ns
(Continued)
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of PPS, with rUO being the main parameter used to assess 
treatment success. The risk of mechanical injury to the uri-
nary tract and incidence of bacterial infection have been 
reported to increase with the duration of catheterisation. 
Catheterisation in the current study was limited to 2 days 
(48 h).44 A retrospective study showed that a duration of 
catheterisation >26 h may be associated with a lower prob-
ability of short-term rUO,45 which may have caused the 
relatively low rate of rUO in the present study.
In all of the cats included in the present study, haematu-
ria and proteinuria decreased significantly, which is 
expected with bladder irrigation and drainage. The 
improvement in haematuria in the placebo group was 
only observed in the dipstick evaluation, whereas in the 
PPS group, there was a significant improvement of micro-
scopic haematuria. Counting cells in microscopic analysis 
is more sensitive than dipstick evaluation, which can show 
colour changes in the presence of not just intact erythro-
cytes, but also haemoglobin and myoglobin. In this study, 
there was only a small difference with regard to absolute 
numbers of haematuria and proteinuria of the PPS and the 
placebo group between days. Although statistically sig-
nificant, these results probably are not clinically relevant.
The limitations of this study include the small sample 
size and inability to collect samples from all of cats at all 
time points. Consequently, comparisons between the 
groups suffered from a low statistical power and were 
prone to type II errors. Secondly, retrograde urethrogra-
phy or urethroscopy was not performed in these patients. 
Therefore, strictures of the urethra and radiolucent ure-
throliths may have been missed.
Conclusions
This study was not able to show that repeated intravesical 
instillation of PPS three times within 48 h into the urinary 
bladder has any apparent beneficial effect on decreasing 
the recurrence rate of UO, as well as clinical signs in cats 
with obstructive FIC. No adverse effects of intravesical 
PPS administration were observed.
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